Young Soo Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Young Soo Park has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- Nayoung Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
38 shared publications - Cheol Min Shin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
35 shared publications - Hyuk Yoon
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
33 shared publications - Dong Ho Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
32 shared publications - Yonghoon Choi
Department of Internal Medicine, Seoul National University Bundang Hospital , Seongnam
19 shared publications - Yu Kyung Jun
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
16 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Frequency and Risk Factors for Difficult-to-Treat Inflammatory Bowel Disease among Patients Receiving Advanced Therapies in a Korean Tertiary-Care Cohort
Jung Hyun Noh, Ho-Kyoung Lee, Yu Kyung Jun, Jinju Choi, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Hyuk Yoon. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260144
- 12 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Open AccessFrequency and Risk Factors for Difficult-to-Treat Inflammatory Bowel Disease among Patients Receiving Advanced Therapies in a Korean Tertiary-Care Cohort
Jung Hyun Noh, Ho-Kyoung Lee, Yu Kyung Jun, Jinju Choi, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Hyuk Yoon. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260144
- 4 November 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (2) , 245-252
Trends and Impacts of Advanced Therapy on Chronic Opioid Use in Asian Patients with Inflammatory Bowel Disease
Objective: Opioid use in Asian patients with inflammatory bowel disease (IBD) remains poorly understood. This study aimed to investigate the trends in chronic opioid use, associated clinical factors, and effects of advanced therapy (AT) on opioid use in Korean patients with IBD. Methods: This nationwide cohort study used administrative claims data from the Korean National Health Insurance Service (2010-2022). Chronic opioid use was defined as opioid use for ≥90 days or ≥3 prescriptions within a calendar year. Logistic regression was used to identify clinical factors associated with chronic opioid use. The impact of AT on opioid use was analyzed through pre- and post-initiation comparisons using McNemar’s tests, generalized estimating equations (GEE), and a linear mixed model. Results: Chronic opioid use increased over the study period, with a higher prevalence in Crohn’s disease (CD) than in ulcerative colitis (UC) (CD: 1.38%, UC: 0.53% in 2010; CD: 5.38%, UC: 1.98% in 2020). Among 49 548 newly diagnosed IBD patients, female sex, steroid and immunomodulator treatments, hospitalizations, emergency room visits, and mental disorders were positively associated with chronic opioid use in CD and UC. AT was positively associated with chronic opioid use in UC (odds ratio [OR] 1.627, P < .0001) but negatively associated with CD (OR 0.786, P = .0013). In CD, AT significantly reduced opioid users (McNemar’s test: P < .0001; GEE: OR 0.478, P < .0001) and average daily doses (mean difference −15.8 morphine milligram equivalents, P = .0073). Conclusion: Chronic opioid use has increased over the past decade among Korean patients with IBD, particularly among those with CD. AT is crucial for reducing opioid use in patients with CD.
- 4 November 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (2) , 245-252
Trends and Impacts of Advanced Therapy on Chronic Opioid Use in Asian Patients with Inflammatory Bowel Disease
Objective: Opioid use in Asian patients with inflammatory bowel disease (IBD) remains poorly understood. This study aimed to investigate the trends in chronic opioid use, associated clinical factors, and effects of advanced therapy (AT) on opioid use in Korean patients with IBD. Methods: This nationwide cohort study used administrative claims data from the Korean National Health Insurance Service (2010-2022). Chronic opioid use was defined as opioid use for ≥90 days or ≥3 prescriptions within a calendar year. Logistic regression was used to identify clinical factors associated with chronic opioid use. The impact of AT on opioid use was analyzed through pre- and post-initiation comparisons using McNemar’s tests, generalized estimating equations (GEE), and a linear mixed model. Results: Chronic opioid use increased over the study period, with a higher prevalence in Crohn’s disease (CD) than in ulcerative colitis (UC) (CD: 1.38%, UC: 0.53% in 2010; CD: 5.38%, UC: 1.98% in 2020). Among 49 548 newly diagnosed IBD patients, female sex, steroid and immunomodulator treatments, hospitalizations, emergency room visits, and mental disorders were positively associated with chronic opioid use in CD and UC. AT was positively associated with chronic opioid use in UC (odds ratio [OR] 1.627, P < .0001) but negatively associated with CD (OR 0.786, P = .0013). In CD, AT significantly reduced opioid users (McNemar’s test: P < .0001; GEE: OR 0.478, P < .0001) and average daily doses (mean difference −15.8 morphine milligram equivalents, P = .0073). Conclusion: Chronic opioid use has increased over the past decade among Korean patients with IBD, particularly among those with CD. AT is crucial for reducing opioid use in patients with CD.
- Open Access
- 31 October 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 483-490
A real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease
Background/Aims: We compared intravenous and subcutaneous infliximab (IFX) as treatment for inflammatory bowel disease (IBD). Methods: This retrospective, multicenter, observational study enrolled patients treated with either intravenous or subcutaneous IFX. Sequential parameters were compared at baseline, 6 months, and 12 months following the initiation of treatment with either type of IFX. The primary outcome was the comparison of the IFX trough levels after 12 months of treatment.Results: In total, 183 participants were included in this study. After 6 months, the subcutaneous group exhibited significant differences compared to the intravenous group; in terms of clinical disease activity (0% vs. 15%, P= 0.007) and IFX trough level (21.72 ± 8.71 μg/mL vs. 7.70 ± 16.65 μg/mL, P= 0.002). After 12 months, subcutaneous, as compared to intravenous, achieved improved clinical disease activity (0% vs. 15%, P= 0.044) and IFX trough level (20.41 ± 12.91 μg/mL vs. 7.06 ± 6.81 μg/mL, P< 0.001). Analyzing the sequential changes compared with baseline data within each group, we observed significant alterations in subcutaneous; 6 months fecal calprotectin (676.3 ± 976.6 μg/g vs. 253.9 ± 483.9 μg/g, P= 0.014), 6 months IFX trough level (7.00 ± 5.67 μg/mL vs. 18.44 ± 6.34 μg/mL, P= 0.026), and 12 months IFX trough level (7.00 ± 5.67 μg/mL vs. 21.33 ± 4.50 μg/mL, P= 0.034).Conclusions: This study indicates the potential suitability of subcutaneous IFX as an alternative treatment option for IBD.
- 31 October 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 483-490
Open AccessA real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease
Background/Aims: We compared intravenous and subcutaneous infliximab (IFX) as treatment for inflammatory bowel disease (IBD). Methods: This retrospective, multicenter, observational study enrolled patients treated with either intravenous or subcutaneous IFX. Sequential parameters were compared at baseline, 6 months, and 12 months following the initiation of treatment with either type of IFX. The primary outcome was the comparison of the IFX trough levels after 12 months of treatment.Results: In total, 183 participants were included in this study. After 6 months, the subcutaneous group exhibited significant differences compared to the intravenous group; in terms of clinical disease activity (0% vs. 15%, P= 0.007) and IFX trough level (21.72 ± 8.71 μg/mL vs. 7.70 ± 16.65 μg/mL, P= 0.002). After 12 months, subcutaneous, as compared to intravenous, achieved improved clinical disease activity (0% vs. 15%, P= 0.044) and IFX trough level (20.41 ± 12.91 μg/mL vs. 7.06 ± 6.81 μg/mL, P< 0.001). Analyzing the sequential changes compared with baseline data within each group, we observed significant alterations in subcutaneous; 6 months fecal calprotectin (676.3 ± 976.6 μg/g vs. 253.9 ± 483.9 μg/g, P= 0.014), 6 months IFX trough level (7.00 ± 5.67 μg/mL vs. 18.44 ± 6.34 μg/mL, P= 0.026), and 12 months IFX trough level (7.00 ± 5.67 μg/mL vs. 21.33 ± 4.50 μg/mL, P= 0.034).Conclusions: This study indicates the potential suitability of subcutaneous IFX as an alternative treatment option for IBD.
- Open Access
- 30 October 2025
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 31 (4) , 462-476
Predictors of Treatment Response to Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Pilot Study
Ho-Kyoung Lee, Cheol Min Shin, Young Hoon Chang, Hyemin Jo, Jinju Choi, Yonghoon Choi, Yu Kyung Jun, Hyuk Yoon, Young Soo Park, Nayoung Kim, and Dong Ho Lee. J Neurogastroenterol Motil 2025;31:462-76. https://doi.org/10.5056/jnm24183
- 30 October 2025
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 31 (4) , 462-476
Open AccessPredictors of Treatment Response to Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Pilot Study
Ho-Kyoung Lee, Cheol Min Shin, Young Hoon Chang, Hyemin Jo, Jinju Choi, Yonghoon Choi, Yu Kyung Jun, Hyuk Yoon, Young Soo Park, Nayoung Kim, and Dong Ho Lee. J Neurogastroenterol Motil 2025;31:462-76. https://doi.org/10.5056/jnm24183
- Open Access
- 17 September 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (2) , 266-274
Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease
Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250188
- 17 September 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (2) , 266-274
Open AccessReal-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease
Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250188
- Open Access
- 18 August 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 385-396
Preventive Effect of Helicobacter pylori Eradication on Osteoporosis in Females: A 20-Year Prospective Observational Cohort Study
Yeejin Kim, Yonghoon Choi, Nayoung Kim, Eun-Bi Jeon, Sung Hye Kong, Jeong Hwan Lee, Ho-Kyoung Lee, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Soyeon Ahn. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250164
- 18 August 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 385-396
Open AccessPreventive Effect of Helicobacter pylori Eradication on Osteoporosis in Females: A 20-Year Prospective Observational Cohort Study
Yeejin Kim, Yonghoon Choi, Nayoung Kim, Eun-Bi Jeon, Sung Hye Kong, Jeong Hwan Lee, Ho-Kyoung Lee, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Soyeon Ahn. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250164
- Open Access
- 30 May 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (6) , 809-820
Role of Serum Pepsinogen Tests in Detection of Gastric Atrophy, Intestinal Metaplasia, Gastric Adenoma, and Gastric Cancer in South Korea
Yonghoon Choi, Nayoung Kim, Ji Hyun Park, Jeong Hwan Lee, Yeejin Kim, Ho-Kyoung Lee, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250055
- 30 May 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (6) , 809-820
Open AccessRole of Serum Pepsinogen Tests in Detection of Gastric Atrophy, Intestinal Metaplasia, Gastric Adenoma, and Gastric Cancer in South Korea
Yonghoon Choi, Nayoung Kim, Ji Hyun Park, Jeong Hwan Lee, Yeejin Kim, Ho-Kyoung Lee, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250055
- Open Access
Assessing Serum Pepsinogen and Helicobacter pylori Tests for Detecting Diffuse-Type Gastric Cancer: Insights from a Large-Scale and Propensity-Score-Matched Study in Republic of Korea
The incidence of cancer and its associated mortality have increased over the past several decades
Open AccessAssessing Serum Pepsinogen and Helicobacter pylori Tests for Detecting Diffuse-Type Gastric Cancer: Insights from a Large-Scale and Propensity-Score-Matched Study in Republic of Korea
The incidence of cancer and its associated mortality have increased over the past several decades
- Open Access
- 1 January 2025
- Published by XMLink in Yonsei Medical Journal
- Vol. 66 (1) , 9-15
Smoking Experience before Adulthood Is Associated with an Increased Risk of Developing Ulcerative Colitis in Adult Ex-Smokers
Jun YK, et al. Yonsei Med J. 2025 Jan;66(1):9-15. https://doi.org/10.3349/ymj.2023.0612
- 1 January 2025
- Published by XMLink in Yonsei Medical Journal
- Vol. 66 (1) , 9-15
Open AccessSmoking Experience before Adulthood Is Associated with an Increased Risk of Developing Ulcerative Colitis in Adult Ex-Smokers
Jun YK, et al. Yonsei Med J. 2025 Jan;66(1):9-15. https://doi.org/10.3349/ymj.2023.0612
- Open Access
- 30 December 2024
- Published by Korean Society of Cancer Prevention in Journal of Cancer Prevention
- Vol. 29 (4) , 148-156
Comparison of GastroPanel® and GENEDIA® in Diagnosing Helicobacter pylori Infection and Gastric Lesions
Yonghoon Choi, Nayoung Kim, Seon Hee Lim, Ji Hyun Park, Jeong Hwan Lee, Yeejin Kim, Hyemin Jo, Ho-Kyoung Lee, Jinju Choi, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee. J Cancer Prev 2024;29:148-56. https://doi.org/10.15430/JCP.24.024
- 30 December 2024
- Published by Korean Society of Cancer Prevention in Journal of Cancer Prevention
- Vol. 29 (4) , 148-156
Open AccessComparison of GastroPanel® and GENEDIA® in Diagnosing Helicobacter pylori Infection and Gastric Lesions
Yonghoon Choi, Nayoung Kim, Seon Hee Lim, Ji Hyun Park, Jeong Hwan Lee, Yeejin Kim, Hyemin Jo, Ho-Kyoung Lee, Jinju Choi, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee. J Cancer Prev 2024;29:148-56. https://doi.org/10.15430/JCP.24.024